Elevance Health stock gains as 2027 margin test comes into focus

Elevance Health stock traded at 382.30 euros on Lang & Schwarz at 16:38 CET on Wednesday, November 11, 2026, 1.06 percent above the Xetra close of Tuesday, November 10. The quote is also 2.22 percent above the 374.00 euros cited in the previous ad-hoc-news.de report on November 9.

Margin recovery shapes the outlook

The latest price move gives investors a fresh market reference, but the operating debate remains centered on the quality of Elevance Health's earnings recovery. Management expects Medicaid margins to improve in 2027 after describing 2026 as the trough year.

The previous report highlighted a third-quarter benefit expense ratio of 90.6 percent, an improvement of 70 basis points from a year earlier. At the same time, the expected full-year Medicare Advantage operating margin of at least 2 percent remains below the company's long-term target range of 3 percent to 5 percent.

Higher guidance, unfinished recovery

Elevance Health is targeting adjusted 2026 earnings of at least 29 US dollars per share and set an adjusted earnings baseline of at least 26.75 US dollars for the following growth comparison. Management expects adjusted diluted earnings per share to rise by at least 12 percent in 2027 from that baseline.

The central question for investors is whether reimbursement increases and medical-cost actions can translate into durable Medicaid improvement. The previous analysis also noted a 1.85 US dollar per-share net non-operating benefit in the third quarter, which makes recurring operating earnings an important measure of progress.

January brings the next test

The next scheduled reporting point is expected in January 2027. Investors will likely focus on the benefit expense ratio, Medicaid margin progress and the assumptions behind the 2027 earnings outlook.

For US equity-market context, follow current S&P 500 market reports.

More news and analyses on Elevance Health stock cover the insurer's earnings, margins and outlook.